Prediction of the effectiveness of Sysmex immunosuppressant inhibitor, aiming for practical use

• 2018-06-27
• /
• WPMASTER
• /
• LEAVE A COMMENT

The original press release is at the following URL. Please refer.

http://www.sysmex.co.jp/corporate/news/2018/180404.html

Conclusion of a re-license patent relating to a method for predicting the effect of an immunity checkpoint inhibitor before dosing

April 04, 2018

Immunity Research Co., Ltd. (Location: Minato-ku, Tokyo; Representative Director: Masahiko Fukuzawa, hereinafter “Immunity Research”) is a joint venture between Sysmex Corporation (headquartered in Kobe City, CEO of Chairman and President and Representative Director “Sysmex” Immunity Research has an exclusive non-exclusive license “A patent on a method of forecasting the effect of an immunity checkpoint inhibitor by blood test in advance (hereinafter referred to as” this patent “), a contract to license Sysmex We will inform you that we have concluded.

Immunocheckpoint inhibitors are known to exert high effects on various cancers and attract great attention all over the world. On the other hand, even in patients with the same cancer, there are cases that do not show drug effects, so an examination to confirm the effect before administration is required.

Saitama Medical University International Medical Center Professor, Respiratory Medicine, invented a method to predict the effectiveness of immunity checkpoint inhibitor (nibormab) with high specificity and sensitivity, by examining lymphocytes in the blood . The results of this research were presented at the American Society of Clinical Oncology (ASCO) held in June 2017, and due to its high predictive performance, effective administration of an immunity checkpoint inhibitor and the accompanying cancer treatment We are getting strong interest from medical institutions, pharmaceutical companies, etc. to contribute to the realization of efficient operation.

Immunity research concluded an exclusive ordinary license agreement of this patent with Saitama Medical University on August 3, 2017, aiming for the development and commercialization of diagnostic technology based on this patent.

For the purpose of early commercialization of diagnostic technology (this diagnostic technique) based on this patent, Sysmex and Immunity Research have re – licensed Sysmex for this patent with Immunity Research ‘s exclusive ordinary license I signed a license agreement.

By developing this diagnostic technique, it becomes possible to preliminarily predict the effect of an immunocheck point inhibitor with a small amount of blood without using a cancer tissue, and it is possible to predict the effect of an immunocheck point inhibitor effectively, It is expected that each individual will contribute to the selection of the optimal treatment based on the results of the examination.

Sysmex and Immunity Research aim to make great advances in cancer therapy by putting into practical use the efficacy diagnostic technology of immunity checkpoint inhibitors at an early stage.

Go Back to Innovation